Trial Profile

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 2256098 (Primary) ; Abemaciclib; Capivasertib; Vismodegib
Indications Meningioma
Focus Therapeutic Use

Most Recent Events

06 Sep 2024 Planned End Date changed from 1 Oct 2024 to 1 Jan 2028.
06 Sep 2024 Planned primary completion date changed from 1 Oct 2024 to 1 Jan 2026.
04 Jun 2024 Results(n=83) evaluating the efficacy of abemaciclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, as part of Alliance umbrella trial A071401, a genomically driven phase II study in recurrent or progressive meningioma, presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com